The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Antipsychotics for patients with pain

  • Shin, Sang Wook (Department of Anesthesia and Pain Medicine, Pusan National University) ;
  • Lee, Jin Seong (Department of Psychiatry, Pusan National University) ;
  • Abdi, Salahadin (Department of Pain Medicine, Division of Anesthesia and Critical Care, The University of Texas MD Anderson Cancer Center) ;
  • Lee, Su Jung (Department of Anesthesia and Pain Medicine, Pusan National University) ;
  • Kim, Kyung Hoon (Department of Anesthesia and Pain Medicine, Pusan National University)
  • Received : 2018.09.18
  • Accepted : 2018.12.06
  • Published : 2019.01.01
Download PDF
⟨ Previous Next ⟩

Abstract

Going back to basics prior to mentioning the use of antipsychotics in patients with pain, the International Association for the Study of Pain (IASP) definition of pain can be summarized as an unpleasant experience, composed of sensory experience caused by actual tissue damage and/or emotional experience caused by potential tissue damage. Less used than antidepressants, antipsychotics have also been used for treating this unpleasant experience as adjuvant analgesics without sufficient evidence from research. Because recently developed atypical antipsychotics reduce the adverse reactions of extrapyramidal symptoms, such as acute dystonia, pseudo-parkinsonism, akathisia, and tardive dyskinesia caused by typical antipsychotics, they are expected to be used more frequently in various painful conditions, while increasing the risk of metabolic syndromes (weight gain, diabetes, and dyslipidemia). Various antipsychotics have different neurotransmitter receptor affinities for dopamine (D), 5-hydroxytryptamine (5-HT), adrenergic (${\alpha}$), histamine (H), and muscarinic (M) receptors. Atypical antipsychotics antagonize transient, weak $D_2$ receptor bindings with strong binding to the $5-HT_{2A}$ receptor, while typical antipsychotics block long-lasting, tight $D_2$ receptor binding. On the contrary, antidepressants in the field of pain management also block the reuptake of similar receptors, mainly on the 5-HT and, next, on the norepinephrine, but rarely on the D receptors. Antipsychotics have been used for treating positive symptoms, such as delusion, hallucination, disorganized thought and behavior, perception disturbance, and inappropriate emotion, rather than the negative, cognitive, and affective symptoms of psychosis. Therefore, an antipsychotic may be prescribed in pain patients with positive symptoms of psychosis during or after controlling all sensory components.

Keywords

References

  1. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 1979; 6: 249.
  2. Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006; 5: 133-46. https://doi.org/10.1038/nrd1956
  3. Targum SD. Treating psychotic symptoms in elderly patients. Prim Care Companion J Clin Psychiatry 2001; 3: 156-63. https://doi.org/10.4088/PCC.v03n0402
  4. Leo RJ, Regno PD. Atypical antipsychotic use in the treatment of psychosis in primary care. Prim Care Companion J Clin Psychiatry 2000; 2: 194-204. https://doi.org/10.4088/PCC.v02n0601
  5. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database Syst Rev 2008: CD004844.
  6. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage 2010; 39: 768-78. https://doi.org/10.1016/j.jpainsymman.2009.09.008
  7. Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: past and present. Indian J Psychiatry 2009; 51: 324-6. https://doi.org/10.4103/0019-5545.58304
  8. Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000; 57: 238-55. https://doi.org/10.1093/ajhp/57.3.238
  9. Gottfries CG, Green L. Flupenthixol decanoate--in treatment of out-patients. Acta Psychiatr Scand Suppl 1974; 255:15-24. https://doi.org/10.1111/j.1600-0447.1974.tb08890.x
  10. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1081-90. https://doi.org/10.1016/j.pnpbp.2003.09.004
  11. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 2009; 35: 549-62. https://doi.org/10.1093/schbul/sbp006
  12. Yang AC, Tsai SJ. New targets for schizophrenia treatment beyond the dopamine hypothesis. Int J Mol Sci 2017; 18:1689. https://doi.org/10.3390/ijms18081689
  13. Inada T. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to i ts usage. Tokyo, Seiwa Shoten Publishers. 1996.
  14. Knol W, Keijsers CJ, Jansen PA, van Marum RJ. Systematic evaluation of rating scales for drug-induced parkinsonism and recommendations for future research. J Clin Psychopharmacol 2010; 30: 57-63. https://doi.org/10.1097/JCP.0b013e3181c914b3
  15. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005; 76: 247-65. https://doi.org/10.1016/j.schres.2005.02.013
  16. Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm 1997; 54: 2461-77. https://doi.org/10.1093/ajhp/54.21.2461
  17. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28: 863-73. https://doi.org/10.1002/mds.25475
  18. Skogseid IM. Dystonia--new advances in classification, genetics, pathophysiology and treatment. Acta Neurol Scand 2014; 129: 13-9. https://doi.org/10.1111/ane.12231
  19. Kurlan R, Rabin M L. P seudoparkinsonism: a review of a common nonparkinsonian hypokinetic movement disorder. Adv Parkinson Dis 2013; 2: 108-12. https://doi.org/10.4236/apd.2013.24020
  20. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133-9.
  21. Munetz MR, Schulz SC. Screening for tardive dyskinesia. J Clin Psychiatry 1986; 47: 75-7.
  22. Uhlyar S, Rey JA. Valbenazine (Ingrezza): the first FDAapproved treatment for tardive dyskinesia. P T 2018; 43: 328-31.
  23. Markowitz JD, Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgmont) 2008; 5: 29-36. https://doi.org/10.1383/psyt.2006.5.1.29
  24. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27-38.
  25. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61: 16-21. https://doi.org/10.4088/JCP.v61n0105
  26. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004; 6: 3-7. https://doi.org/10.4088/PCC.v06n0101
  27. Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L'italien GJ, Stockdale W, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother 2006; 40: 626-32. https://doi.org/10.1345/aph.1G564
  28. Gentile S. Contributing factors to weight gain during longterm treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obes Rev 2009; 10: 527-42. https://doi.org/10.1111/j.1467-789X.2009.00589.x
  29. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychoticinduced weight gain: insights into mechanisms of action. CNS Drugs 2011; 25: 1035-59. https://doi.org/10.2165/11596300-000000000-00000
  30. Taylor DM, McAskill R. Atypical antipsychotics and weight gain--a systematic review. Acta Psychiatr Scand 2000; 101: 416-32. https://doi.org/10.1034/j.1600-0447.2000.101006416.x
  31. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004; 37: 1-11.
  32. Schwenkreis P, Assion HJ. Atypical antipsychotics and diabetes mellitus. World J Biol Psychiatry 2004; 5: 73-82. https://doi.org/10.1080/15622970410029915
  33. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62: 15-26.
  34. Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014; 40: 314-26. https://doi.org/10.1093/schbul/sbu001
  35. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, Cipriani A, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 2015; 41: 1397-402. https://doi.org/10.1093/schbul/sbv037
  36. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64: 663-7. https://doi.org/10.4088/JCP.v64n0607
  37. Khouzam HR. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics. Postgrad Med 2016; 128: 323-30. https://doi.org/10.1080/00325481.2016.1147925
  38. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172: 1703-11. https://doi.org/10.1503/cmaj.1041064